ARMATA PHARMACEUTICALS, INC. (ARMP) Current Ratio
- Current ratio · latest quarter: Value 0.11×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.11× | Current assets / current liabilities. $27.16M ÷ $250.20M ≈ 0.11× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 27.16M USD | Assets, Current |
| Current obligations | 250.20M USD | Liabilities, Current |
| Cash and equivalents | 23.95M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.19M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $27.16M | $250.20M | $23.95M | (m) | (m) | (m) | $1.19M | (m) | 0.11× |
| 2026-03-31 | $5.95M | $9.23M | $4.75M | (m) | (m) | (m) | $660.00K | (m) | 0.64× |
| 2025-12-31 | $10.67M | $8.95M | $8.69M | (m) | (m) | (m) | $921.00K | (m) | 1.19× |
| 2025-09-30 | $16.93M | $139.95M | $14.76M | (m) | (m) | (m) | $1.28M | (m) | 0.12× |
| 2025-06-30 | $7.52M | $120.08M | $4.33M | (m) | (m) | (m) | $965.00K | (m) | 0.06× |
| 2025-03-31 | $13.17M | $110.54M | $11.69M | (m) | (m) | (m) | $981.00K | (m) | 0.12× |
| 2024-12-31 | $11.31M | $48.25M | $9.29M | (m) | (m) | (m) | $766.00K | (m) | 0.23× |
| 2024-09-30 | $22.39M | $118.20M | $17.14M | (m) | (m) | (m) | $1.81M | (m) | 0.19× |
| 2024-06-30 | $30.90M | $123.18M | $26.41M | (m) | (m) | (m) | $1.74M | (m) | 0.25× |
| 2024-03-31 | $41.72M | $110.05M | $37.86M | (m) | (m) | (m) | $2.06M | (m) | 0.38× |
| 2023-12-31 | $19.15M | $16.46M | $13.52M | (m) | (m) | (m) | $1.58M | (m) | 1.16× |
| 2023-09-30 | $36.59M | $21.88M | $23.96M | (m) | (m) | (m) | $3.77M | (m) | 1.67× |
| 2023-06-30 | $26.83M | $51.56M | $12.46M | (m) | (m) | (m) | (m) | (m) | 0.52× |
| 2023-03-31 | $38.59M | $51.41M | $25.11M | (m) | (m) | (m) | (m) | (m) | 0.75× |
| 2022-12-31 | $27.05M | $24.87M | $14.85M | (m) | (m) | (m) | $1.68M | (m) | 1.09× |
| 2022-09-30 | $33.24M | $7.00M | $25.38M | (m) | (m) | (m) | (m) | (m) | 4.75× |
| 2022-06-30 | $41.31M | $7.38M | $36.98M | (m) | (m) | (m) | (m) | (m) | 5.59× |
| 2022-03-31 | $48.70M | $6.23M | $46.41M | (m) | (m) | (m) | (m) | (m) | 7.82× |
| 2021-12-31 | $14.99M | $4.81M | $10.29M | (m) | (m) | (m) | $1.14M | (m) | 3.11× |
| 2021-09-30 | $14.18M | $5.25M | $12.08M | (m) | (m) | (m) | (m) | (m) | 2.70× |
| 2021-06-30 | $19.71M | $5.90M | $17.54M | (m) | (m) | (m) | (m) | (m) | 3.34× |
| 2021-03-31 | $24.04M | $4.98M | $22.45M | (m) | (m) | (m) | (m) | (m) | 4.83× |
| 2020-12-31 | $10.85M | $6.71M | $9.65M | (m) | (m) | (m) | $956.00K | (m) | 1.62× |
| 2020-09-30 | $17.02M | $7.07M | $15.88M | (m) | (m) | (m) | (m) | (m) | 2.41× |
| 2020-06-30 | $20.68M | $5.21M | $19.79M | (m) | (m) | (m) | (m) | (m) | 3.97× |
| 2020-03-31 | $25.78M | $6.36M | $24.21M | (m) | (m) | (m) | (m) | (m) | 4.05× |
| 2019-12-31 | $6.66M | $4.88M | $6.03M | (m) | (m) | (m) | $547.00K | (m) | 1.36× |
| 2019-09-30 | $9.93M | $4.96M | $8.69M | (m) | (m) | (m) | (m) | (m) | 2.00× |
| 2019-06-30 | $14.20M | $5.63M | $13.19M | (m) | (m) | (m) | (m) | (m) | 2.52× |
| 2019-03-31 | $5.94M | $3.59M | $5.54M | (m) | (m) | (m) | (m) | (m) | 1.65× |
| 2018-12-31 | $10.36M | $2.03M | $9.66M | (m) | (m) | (m) | $415.00K | (m) | 5.10× |
| 2018-09-30 | $5.11M | $2.46M | $4.50M | (m) | (m) | (m) | $714.00K | (m) | 2.07× |
| 2018-06-30 | $6.12M | $2.05M | $5.80M | (m) | (m) | (m) | $682.00K | (m) | 2.99× |
| 2018-03-31 | $8.74M | $1.77M | $8.21M | (m) | (m) | (m) | $810.00K | (m) | 4.93× |
| 2017-12-31 | $5.38M | $1.97M | $5.13M | (m) | (m) | (m) | $578.00K | (m) | 2.74× |
| 2017-09-30 | $7.99M | $2.48M | $7.72M | (m) | (m) | (m) | (m) | (m) | 3.23× |
| 2017-06-30 | $9.24M | $3.71M | $8.96M | (m) | (m) | (m) | (m) | (m) | 2.49× |
| 2017-03-31 | $2.56M | $2.88M | $2.20M | (m) | $15.00K | (m) | (m) | (m) | 0.89× |
| 2016-12-31 | $6.31M | $3.54M | $5.71M | (m) | (m) | (m) | $1.06M | (m) | 1.78× |
| 2016-09-30 | $4.56M | $3.15M | $3.97M | (m) | $24.00K | (m) | (m) | (m) | 1.45× |
| 2016-06-30 | $7.74M | $3.32M | $7.14M | (m) | $18.00K | (m) | (m) | (m) | 2.33× |
| 2016-03-31 | $6.75M | $2.65M | $6.17M | (m) | $14.00K | (m) | (m) | (m) | 2.55× |
| 2015-12-31 | $10.02M | $2.38M | $9.37M | (m) | $125.00K | (m) | (m) | (m) | 4.20× |
| 2015-09-30 | $12.56M | $2.26M | $11.74M | (m) | $40.00K | (m) | (m) | (m) | 5.56× |
| 2015-06-30 | $14.86M | $2.17M | $14.35M | (m) | (m) | (m) | (m) | (m) | 6.86× |
| 2015-03-31 | $17.04M | $2.12M | $16.63M | (m) | $0.00 | (m) | (m) | (m) | 8.03× |
| 2014-12-31 | $7.02M | $1.87M | $6.58M | (m) | $100.00K | (m) | (m) | (m) | 3.76× |
| 2014-09-30 | $10.26M | $2.54M | $9.79M | (m) | $27.00K | (m) | (m) | (m) | 4.05× |
| 2014-06-30 | $13.21M | $1.72M | $12.55M | (m) | $136.00K | (m) | (m) | (m) | 7.70× |
| 2014-03-31 | $16.79M | $1.03M | $16.43M | (m) | $12.00K | (m) | (m) | (m) | 16.37× |
| 2013-12-31 | $20.66M | $2.39M | $20.36M | (m) | $8.00K | (m) | (m) | (m) | 8.64× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |